



Sveriges lantbruksuniversitet
Swedish University of Agricultural Sciences

Institutionen för Molekylära Vetenskaper
Department of Molecular Sciences

Optimization of probiotic capacity

Project focusing on assessing interactions between *L. reuteri* and host cells and the correlation to production parameters

Ludwig Lundqvist, Industrial PhD. student

Lactobacillus reuteri

- Among the worlds most studied probiotic bacteria
- Clinically proven in a variety of different research fields
 - Paediatric health:
 - Reduced crying-time in infant colic ⁽¹⁾
 - Preventive of diarrhoea ⁽²⁾
 - Various other implications ⁽³⁾
 - Adult health:
 - Preventive of periodontal disease and gingivitis
 - *Helicobacter pylori* infections



- (1) Meta-analysis by Sung et al 2017. Published in Paediatrics
- (2) Randomised Clinical Trial by Francavilla et al. 2012. Published in Alimentary pharmacology and therapeutics
- (3) Review on L.reuteri in children by Magdalena Urbańska and Hania Szajewska 2014. Published in European journal of pediatrics.

Factors

Different productions parameters

pH
Oxygen pressure
Carbon source
Starvation mode

Production:

Cultivation
Formulation
Desiccation (freeze-drying)



Responses

Traditional:

Production survival,
storage stability

Developed herein:

vitality
+ stress tolerance
+ bioactivity
+ probiotic capacity



Aims

- Overall aim to increase the potency of *L. reuteri*
 - Better understand the impact of production/production parameters on stress tolerance and bioactivity
 - Acquire further knowledge concerning the underlying molecular mechanisms of increased stress tolerance and bioactivity
- Assess genomic and metabolomic changes in lyophilized *L. reuteri*
 - Better understand changes associated with genes and/or genetic expression giving rise to changes in probiotic properties and vitality.

Methods

- Fermentation, formulation and lyophilization
- Cell lines simulating conditions of interest
 - Expresses differentiation properties of intestinal epithelial cells
 - Simulation of inflammation
 - Intestinal porcine enterocytes reflecting epithelial functionality
 - Functional pain cell line
- Potentially animal trials



BioGaia®

Probiotics grounded in evolution
Driven by science




**NETWORK
Researchers**
Preclinical and clinical
studies at hospitals
and universities

BioGaia
Product development
Product strategies
Research
Quality assurance system
Marketing support
IP

**NETWORK
Partners**
Pharmaceutical or
healthcare companies
with sales
organizations

**NETWORK
Suppliers**
Production and
packaging

- BioGaia
- Universities and hospitals where research is conducted
- Manufacturing and packaging units
- Partners with sales of products





MISSION

BioGaia conducts research and development to offer consumers clinically-proven, health-promoting, patented and user-friendly probiotic products



VISION

BioGaia's vision is to be a ground-breaking leader in probiotics



- Collaborations
 - Worldwide research network
 - SLU
 - Lund University
- Preclinical studies guide collaborating partners
- Brand new research facility in Eslöv
 - Main location switch in two years



References

- 1. <http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=29279326>
- 2. <https://www.ncbi.nlm.nih.gov/pubmed/22680836>
- 3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165878/table/Tab1/?report=objectonly>